Lipophilic pyrazinoic acid amide and ester prodrugs. Stability, activation and activity against M. tuberculosis

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 257-263

  Simões, Marta Filipa ^a   Valente, Emília ^a   Gómez, M José Rodríguez ^a,b   Anes, Elsa ^a   Constantino, Luís ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Esterases; Pyrazinamide; Pyrazinoic acid; Tuberculosis

Indexed keywords

BUTYLPYRAZINOATE; DODECYLPYRAZINOATE; ESTER DERIVATIVE; HEXADECYLPYRAZINOATE; N DODECYLPYRAZINAMIDE; N HEXADECYLPYRAZINAMIDE; N TETRADECYLPYRAZINAMIDE; PYRAZINOIC ACID; PYRAZINOIC ACID DERIVATIVE; TETRADECYLPYRAZINOATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CYTOTOXICITY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; LIVER HOMOGENATE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIDES; ANIMALS; ANTITUBERCULAR AGENTS; BUFFERS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ESTERS; HUMANS; HYDROLYSIS; INDICATORS AND REAGENTS; LIPIDS; LIVER; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS; PRODRUGS; PYRAZINAMIDE; RATS; SOLUBILITY; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 67349098841     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.02.012     Document Type: Article

References (28)

1. Anes E., Kühnel M., Bos E., Moniz-Pereira J., Habermann A., and Griffiths G. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat. Cell. Biol. 5 (2003) 793-802
2. Anes E., Peyron P., Staali L., Jordao L., Gutierrez M., Kress H., Hagedorn M., Maridonneau-Parini I., Skinner M., Wildeman A., Kalamidas S., Kuehnel M., and Griffiths G. Dynamic life and death interactions between Mycobacterium smegmatis and J774 macrophages. Cell. Microbiol. 8 (2006) 939-960
3. Bergmann K., Cynamon M., and Welch J. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J. Med. Chem. 39 (1996) 3394-3400
4. Cheng S., Thibert L., Sanchez T., Heifets L., and Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44 (2000) 528-532
5. Cole S., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S., Eiglmeier K., Gas S., Barry C.r., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J., Quail M., Rajandream M., Rogers J., Rutter S., Seeger K., Skelton J., Squares R., Squares S., Sulston J., Taylor K., Whitehead S., and Barrell B. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
6. Connel N.D., and Nikaido H. Membrane permeability and transport in Mycobacterium tuberculosis. In: Bloom B.R. (Ed). Tuberculosis Pathogenesis, Protection and Control (1994), AFM Press, Washington, DC 333-351
7. Constantino L., Paixão P., Moreira R., Portela M., Do Rosario V., and Iley J. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp. Toxicol. Pathol. 51 (1999) 299-303
8. Cynamon M., Gimi R., Gyenes F., Sharpe C., Bergmann K., Han H., Gregor L., Rapolu R., Luciano G., and Welch J. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. 38 (1995) 3902-3907
9. Cynamon M., Klemens S., Chou T., Gimi R., and Welch J. Antimycobacterial activity of a series of pyrazinoic acid esters. J. Med. Chem. 35 (1992) 1212-1215
10. Dickinson P., and Taylor G. Pulmonary and blood enzyme-kinetics as predictors of pulmonary metabolism of esters. Int. J. Pharmaceut. 116 (1995) 231-236
11. Gu P., Constantino L., and Zhang Y. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J. Med. Microbiol. 57 (2008) 1129-1134
12. Heifets L.B. Pyrazinamide. In: Yu V.L., Merigan T.C., and Barriere S.L. (Eds). Antimicrobial Therapy and Vaccines (1999), Williams and Wilkins, Baltimore, MD 668-676
13. Jordao L., Lengeling A., Bordat Y., Boudou F., Gicquel B., Neyrolles O., Becker P., Guzman C., Griffiths G., and Anes E. Effects of omega-3 and -6 fatty acids on Mycobacterium tuberculosis in macrophages and in mice. Microbe. Infect. 10 (2008) 1379-1386
14. Kalamidas S., Kuehnel M., Peyron P., Rybin V., Rauch S., Kotoulas O., Houslay M., Hemmings B., Gutierrez M., Anes E., and Griffiths G. cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria. J. Cell. Sci. 119 (2006) 3686-3694
15. Konno K., Feldmann F., and McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95 (1967) 461-469
16. Li B., Sedlacek M., Manoharan I., Boopathy R., Duysen E., Masson P., and Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 70 (2005) 1673-1684
17. Maag H. Prodrugs of Carboxylic Acids. In: Stella V.J., Borchardt R.T., Hageman M.J., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards (2007), Springer, New York 3-30
18. McCune R.J., McDermott W., and Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104 (1956) 763-802
19. Portugal I., Barreiro L., Moniz-Pereira J., and Brum L. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48 (2004) 2736-2738
20. Strober, W., 2001. Trypan blue exclusion test of cell viability. Curr. Protoc. Immunol. Appendix 3, Appendix 3B.
21. Testa B., and Mayer J.M. The hydrolysis of carboxylic acid ester prodrugs. In: Testa B., and Mayer J.M. (Eds). Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (2003), VHCA/Wiley-VCH, Zurich 419-534
22. Wan H., Williams R., Doherty P., and Williams D. A study of the reproducibility of the MTT test. J. Mater. Sci. Mater. Med. 5 (1994) 154-159
23. Wang R., and Marcotte E. The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways. J. Proteome Res. 7 (2008) 855-865
24. Yamamoto S., Toida I., Watanabe N., and Ura T. In vitro antimycobacterial activities of pyrazinamide analogs. Antimicrob. Agents Chemother. 39 (1995) 2088-2091
25. Yates R., Hermetter A., and Russell D. The kinetics of phagosome maturation as a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. Traffic 6 (2005) 413-420
26. Zhang Y., and Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7 (2003) 6-21
27. Zhang Y., Permar S., and Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51 (2002) 42-49
28. Zhang Y., Zhang H., and Sun Z. Susceptibility of Mycobacterium tuberculosis to weak acids. J. Antimicrob. Chemother. 52 (2003) 56-60